A phase II trial of murine monoclonal antibody 17-1A and interferon-gamma: clinical and immunological data.
A group of 15 patients with metastatic colorectal adenocarcinoma received a combination of interferon gamma (0.1 mg/m2, days 1-15) and the murine monoclonal antibody 17-1A (400 mg, days 5, 7, 9 and 12). The treatment was tolerated with minimal toxicity. Of the 14 evaluable patients, 13 developed human antibody to murine 17-1A, with 11 patients demonstrating antibody to the variable region of 17-1A (anti-idiotype). Antibody to the variable region was inhibited by 17-1A but not by mouse immunoglobulin. Sera from patients with substantial anti-idiotype reactivity were capable of inhibiting the binding of murine 17-1A to antigen expressing LS174-T cells thus indicating the presence of antibody directed against the 17-1A combining site (mirror-image anti-idiotype). The median survival of the whole group was 56 weeks and there was no correlation between clinical response/survival and the development of anti-idiotype antibody.
Saleh
M N
MN
Comprehensive Cancer Center, University of Alabama, Birmingham 35294.
LoBuglio
A F
AF
Wheeler
R H
RH
Rogers
K J
KJ
Haynes
A
A
Lee
J Y
JY
Khazaeli
M B
MB
D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy* / Q000276:immunology / Q000556:secondary; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000917:Antibody Formation / Q000276:immunology; D003110:Colonic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000276:immunology / Q000556:secondary; D004341:Drug Evaluation; D006801:Humans; D007371:Interferon-gamma / Q000627:therapeutic use* / Q000633:toxicity; D007958:Leukocyte Count / Q000187:drug effects; D051379:Mice; D011994:Recombinant Proteins
D000911:Antibodies, Monoclonal; D011994:Recombinant Proteins; D007371:Interferon-gamma